Scalper1 News
Specialty drugmaker Sucampo Pharmaceuticals (SCMP) beat Q2 expectations and raised its guidance early Wednesday, sending the stock to a new high in early trading. It pulled back later, however, possibly because word got out that its sole marketed drug is being excluded from CVS’ (CVS) preferred formulary next year. Sucampo reported earnings of 21 cents a share, up from just 4 cents in the year-earlier quarter and 6 cents above analysts’ consensus, Scalper1 News
Scalper1 News